ITGA2B

Integrin alpha-IIb · P08514 · ITGA2B on Sugi Atlas →

143,773 patent compounds predicted against ITGA2B, 69,634 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tirofiban (SCHEMBL3685)	1.00	20/20
Tirofiban (SCHEMBL41327)	0.98	20/20
Tirofiban (SCHEMBL155170)	0.98	20/20
Tirofiban (SCHEMBL41325)	0.96	20/20
Tirofiban (SCHEMBL140366)	0.96	20/20
Tirofiban (SCHEMBL41326)	0.95	20/20
Roxifiban (SCHEMBL50632)	0.86	20/20
Lamifiban (SCHEMBL4683)	1.00	17/20
SCHEMBL246301	0.81	17/20
Lotrafiban (SCHEMBL29596)	1.00	14/20
Xemilofiban (SCHEMBL50663)	1.00	14/20
SCHEMBL243197	0.54	12/20
SCHEMBL254638	0.53	12/20
SCHEMBL29945	0.67	11/20
Sibrafiban (SCHEMBL50759)	1.00	10/20
SCHEMBL244700	0.63	10/20
SCHEMBL244300	0.66	9/20
SCHEMBL241017	0.59	9/20
SCHEMBL241018	0.59	9/20
SCHEMBL119886	0.57	9/20

Clinical trials — most relevant to ITGA2B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO	PHASE2	RECRUITING
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I	PHASE1	WITHDRAWN
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors	PHASE1	COMPLETED
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients	EARLY_PHASE1	UNKNOWN
An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, in Patients With Malignant Tumors	EARLY_PHASE1	NOT_YET_RECRUITING
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients	EARLY_PHASE1	COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Myocardial Infarction	EARLY_PHASE1	UNKNOWN
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)	nan	COMPLETED
ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract Cancer	nan	UNKNOWN
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications	nan	COMPLETED
Angiogenesis and Fibrosis in Aortic Stenosis	nan	COMPLETED
Angiogenesis and Fibrosis in Myocardial Infarction	nan	COMPLETED
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer	nan	COMPLETED
Early Regenerative Intervention for Post-Traumatic Osteoarthritis	nan	UNKNOWN
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis	nan	UNKNOWN
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer	nan	COMPLETED
Clinical Pattern of Glanzemnn Thrombathenia in Children Attending Assiut University Children Hospital	nan	NOT_YET_RECRUITING
CancerenD24 Screening as an Aid to the Clinician for the Diagnosis of Cancer	nan	RECRUITING
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects	nan	UNKNOWN
IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types	nan	COMPLETED
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage	nan	COMPLETED
The MyoThrombus Study	nan	COMPLETED
JAK2V617F Mutated Endothelium Has a Stem Cell Potential in Primary Myelofibrosis: a New Disease Ontogenesis for Chronic Myeloproliferative Disorders	nan	COMPLETED
No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track	nan	RECRUITING
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ITGA2B binder may also engage these)

Protein	Name	Similarity
P11688	—	0.999	P11688 →
ITGA5	Integrin alpha-5	0.999	landscape →
Q13683	—	0.998	Q13683 →
Q9QUM0	—	0.997	Q9QUM0 →
O75578	—	0.995	O75578 →
F1MMS9	—	0.995	F1MMS9 →
Q62470	—	0.994	Q62470 →
P26006	—	0.993	P26006 →
P53711	—	0.992	P53711 →
ITGAL	Integrin alpha-L	0.991	landscape →
Q63258	—	0.988	Q63258 →
P17852	—	0.988	P17852 →
P38570	—	0.987	P38570 →
Q27977	—	0.987	Q27977 →
P24063	—	0.987	P24063 →
Q61738	—	0.987	Q61738 →
Q3V0T4	—	0.983	Q3V0T4 →
Q9QYE7	—	0.982	Q9QYE7 →
P43406	—	0.981	P43406 →
Q06274	—	0.980	Q06274 →
D3ZLH5	—	0.979	D3ZLH5 →
ITGAM	Integrin alpha-M	0.978	landscape →
Q9C0C4	—	0.978	Q9C0C4 →
Q13349	—	0.978	Q13349 →
P61625	—	0.977	P61625 →
B8JK39	—	0.977	B8JK39 →
Q9NS98	—	0.977	Q9NS98 →
P61622	—	0.977	P61622 →
Q9QY40	—	0.977	Q9QY40 →
Q13797	—	0.976	Q13797 →